BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chavan P, Chikahisa S, Shiuchi T, Shimizu N, Dalanon J, Okura K, Séi H, Matsuka Y. Dual orexin receptor antagonist drug suvorexant can help in amelioration of predictable chronic mild stress-induced hyperalgesia. Brain Res Bull 2022:S0361-9230(22)00174-5. [PMID: 35868501 DOI: 10.1016/j.brainresbull.2022.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mogavero MP, Silvani A, Lanza G, DelRosso LM, Ferini-Strambi L, Ferri R. Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations. Nat Sci Sleep 2023;15:17-38. [PMID: 36713640 DOI: 10.2147/NSS.S201994] [Reference Citation Analysis]
2 Franco-garcía A, Guerrero-bautista R, Hidalgo JM, Milanés MV, Gómez-murcia V, Núñez C. Differential role of dopamine D3 receptor through balanced modulation of Akt/mTOR and ERK1/2 activity in the reactivation of cocaine rewarding memories evoked by psychological versus physiological stress.. [DOI: 10.1101/2022.09.12.507553] [Reference Citation Analysis]
3 Fukushi I, Yokota S, Takeda K, Terada J, Umeda A, Yoshizawa M, Kono Y, Hasebe Y, Onimaru H, Pokorski M, Okada Y. Dual orexin receptor blocker suvorexant attenuates hypercapnic ventilatory augmentation in mice. Brain Res 2022;:148061. [PMID: 36037880 DOI: 10.1016/j.brainres.2022.148061] [Reference Citation Analysis]